These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 16510466

  • 1. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 2. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):992-8. PubMed ID: 16949492
    [Abstract] [Full Text] [Related]

  • 3. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure.
    Spoladore R, Fragasso G, Perseghin G, De Cobelli F, Esposito A, Maranta F, Calori G, Locatelli M, Lattuada G, Scifo P, Del Maschio A, Margonato A.
    Fundam Clin Pharmacol; 2013 Aug 05; 27(4):455-64. PubMed ID: 22320703
    [Abstract] [Full Text] [Related]

  • 4. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM.
    Eur Heart J; 2004 Oct 05; 25(20):1814-21. PubMed ID: 15474696
    [Abstract] [Full Text] [Related]

  • 5. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.
    Heart; 2011 Sep 05; 97(18):1495-500. PubMed ID: 21700755
    [Abstract] [Full Text] [Related]

  • 6. Cardiac high-energy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy.
    Neubauer S, Horn M, Pabst T, Harre K, Strömer H, Bertsch G, Sandstede J, Ertl G, Hahn D, Kochsiek K.
    J Investig Med; 1997 Oct 05; 45(8):453-62. PubMed ID: 9394098
    [Abstract] [Full Text] [Related]

  • 7. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R.
    Rev Port Cardiol; 2000 Nov 05; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [Abstract] [Full Text] [Related]

  • 8. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.
    Am Heart J; 2003 Nov 05; 146(5):E18. PubMed ID: 14597947
    [Abstract] [Full Text] [Related]

  • 9. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G, Gebara O, Vitale C, Caminiti G, Wajngarten M, Volterrani M, Ramires JA, Rosano G, Fini M.
    Adv Ther; 2009 Apr 05; 26(4):455-61. PubMed ID: 19396409
    [Abstract] [Full Text] [Related]

  • 10. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R, Lacalaprice F, Faccenda E, Volpe L.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct 05; 15(5):533-40. PubMed ID: 18797405
    [Abstract] [Full Text] [Related]

  • 11. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov 05; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 12. Brain death-induced alterations in myocardial workload and high-energy phosphates: a phosphorus 31 magnetic resonance spectroscopy study in the cat.
    Brandon Bravo Bruinsma GJ, Nederhoff MG, te Boekhorst BC, Bredée JJ, Ruigrok TJ, van Echteld CJ.
    J Heart Lung Transplant; 1998 Oct 05; 17(10):984-90. PubMed ID: 9811406
    [Abstract] [Full Text] [Related]

  • 13. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance.
    Leonardo F, Fragasso G, Rossetti E, Dabrowski P, Pagnotta P, Rosano GM, Chierchia SL.
    Cardiologia; 1999 Dec 05; 44(12):1065-9. PubMed ID: 10687257
    [Abstract] [Full Text] [Related]

  • 14. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.
    Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, Henning A, Frenneaux M.
    J Am Coll Cardiol; 2009 Jul 28; 54(5):402-9. PubMed ID: 19628114
    [Abstract] [Full Text] [Related]

  • 15. [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure].
    Ma QL, Xie Y, Zhang SD.
    Hunan Yi Ke Da Xue Xue Bao; 2002 Dec 28; 27(6):527-9. PubMed ID: 12658930
    [Abstract] [Full Text] [Related]

  • 16. Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging.
    Esposito A, De Cobelli F, Perseghin G, Pieroni M, Belloni E, Mellone R, Canu T, Gentinetta F, Scifo P, Chimenti C, Frustaci A, Luzi L, Maseri A, Maschio AD.
    Heart; 2009 Mar 28; 95(3):228-33. PubMed ID: 18708417
    [Abstract] [Full Text] [Related]

  • 17. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G, Bunc M, Vrtovec B.
    J Cardiovasc Pharmacol Ther; 2010 Mar 28; 15(1):31-6. PubMed ID: 19966175
    [Abstract] [Full Text] [Related]

  • 18. Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study.
    Perseghin G, Fiorina P, De Cobelli F, Scifo P, Esposito A, Canu T, Danna M, Gremizzi C, Secchi A, Luzi L, Del Maschio A.
    J Am Coll Cardiol; 2005 Sep 20; 46(6):1085-92. PubMed ID: 16168295
    [Abstract] [Full Text] [Related]

  • 19. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA, Il'ina IuV, Sotnikova TI, Rybakova MK.
    Klin Med (Mosk); 2004 Sep 20; 82(11):15-20. PubMed ID: 15656392
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
    Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ.
    Pharmacotherapy; 2008 Dec 20; 28(12):1461-70. PubMed ID: 19025427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.